A phase II study of biweekly pralatrexate and docetaxel in patients with advanced esophageal and gastroesophageal carcinoma that have failed first-line platinum-based therapy

Journal of Gastrointestinal Oncology

Christina Wu¹  Melissa Yereb¹  Tanios Bekaii-Saab¹  Alison Neal¹  Brian Petullo²  Lai Wei³  Jeffrey Rose¹ 

[1] Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USAComprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USAComprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA;Wexner Medical Center,Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USAWexner Medical Center,Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USAWexner Medical Center,Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA;Center for Biostatistics,Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USACenter for Biostatistics,Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USACenter for Biostatistics,Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA

关键词: Pralatrexate;    docetaxel;    gastrointestinal neoplasms;    esophageal (E) cancer;   

DOI  :  10.3978/j.issn.2078-6891.2015.011

学科分类：肿瘤学

来源: Pioneer Bioscience Publishing Company

【 授权许可】

Unknown